



February 06, 2026

**National Stock Exchange of India Limited,**  
Compliance Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai - 400051,  
Maharashtra, India

**BSE Limited,**  
Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001,  
Maharashtra, India

Dear Sir/Madam,

**Subject :** *Newspaper advertisement of Unaudited Financial Results of HealthCare Global Enterprises Limited (“the Company”).*

**Stock Code :** *BSE – 539787, NSE – HCG*

**Reference :** *Regulation 30, 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”)*

Please find enclosed herewith the copies of newspaper advertisement published in Business Standard (English) and Vijayawani (Kannada) on February 06, 2026 with regard to approval of Unaudited financial results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2025 at the meeting of Board of Directors held on February 05, 2026.

Kindly take the intimation on record.

Thanking you,

For **HealthCare Global Enterprises Limited**

**Sunu Manuel**  
Company Secretary & Compliance Officer

Encl: a/a.

HEALTHCARE GLOBAL ENTERPRISES LIMITED  
Regd Off: HCG Towers, # 8, P Kalinga Rao Road, Sampangi Ram Nagar, Bangalore – 560027  
CIN: L15200KA1998PLC023489  
Phone: +91 – 80 – 4660 7700, Fax: +91 – 80 – 4660 7749  
Email: investors@hcgel.com, Website: www.hgconology.com



EXTRACT OF THE CONSOLIDATED & STANDALONE FINANCIAL RESULTS  
FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

Particulars	Consolidated (Amount in Rs. Lakhs)				Standalone (Amount in Rs. Lakhs)			
	Quarter ended 31 December 2025	Corresponding quarter ended 31 December 2024	Nine months ended 31 December 2025	Previous year ended 31 March 2025	Quarter ended 31 December 2025	Corresponding quarter ended 31 December 2024	Nine months ended 31 December 2025	Previous year ended 31 March 2025
	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
Total income	63,554	56,321	190,500	225,796	34,515	31,780	102,984	131,510
Net profit/ (loss) for the period (before tax and exceptional items)	660	(330)	3,834	5,696	659	(156)	2,643	5,440
Exceptional items, net gain / (loss)	(1,267)	-	(1,267)	-	(786)	(3,482)	(786)	(3,482)
Net profit/ (loss) for the period (after tax and exceptional items)	(790)	775	1,874	4,883	(118)	(3,733)	1,305	353
Net profit / (loss) for the period attributable to equity share holders of the company	(943)	698	1,159	4,441	(118)	(3,733)	1,305	353
Total comprehensive income/(loss) for the period (Comprising net profit and other comprehensive income after tax) attributable to equity share holders of the company	(792)	758	1,405	4,802	(88)	(3,734)	1,324	383
Equity share capital	14,101	13,940	14,101	13,942	14,101	13,940	14,101	13,942
Earnings per share (of Rs.10 each) in Rs.Basic:	(0.68)	0.50	0.82	3.19	(0.08)	(2.68)	0.94	0.25
Earnings per share (of Rs.10 each) in Rs.Diluted:	(0.68)	0.49	0.82	3.14	(0.08)	(2.64)	0.93	0.25

Notes:  
1. The above results were reviewed by the audit committee and approved by the board of directors at their meeting held on 05 February 2026.  
2. The above is an extract from the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the NSE Limited (www.nseindia.com), BSE Limited (www.bseindia.com) and at the Company's website (www.hgconology.com).



For HealthCare Global Enterprises Limited  
Sd/-  
Dr. Manish Mattoo  
Executive Director and Chief Executive Officer

Bengaluru, 5 February 2026



Administrative Office :  
Nagar Panchayat Building, Manchar,  
Ambegaon Taluka, Pune District.  
Phone: (02133) 226539 / 9028226539  
Email : hoshreebhairavnath@gmail.com

IMMOVABLE PROPERTY POSSESSION NOTICE (FORM Z)

(Under Section 156 of the Maharashtra Co-operative Societies Act, 1960 and Rule No. 107 and the sub-rules thereunder)  
This is to inform all concerned that, due to the failure of the following defaulting co-borrowers and their guarantors to repay the loans taken from the institution, the Hon'ble Special Recovery and Sales Officer, Shri Bhairavnath Nagari Sahakari Patsanstha Ltd., Landewadi Chinchodi, Tal. Ambegaon, Dist. Pune, has, pursuant to the recovery certificate obtained under Section 101 of the Maharashtra Co-operative Societies Act, 1960, and in accordance with Bye-law No. 107 11(d-1)1 (First Amendment) of the Maharashtra Co-operative Societies Rules, 1961, and the notification dated 30/08/2014, the institution has taken symbolic possession of the following immovable properties of the defaulting borrowers, co-borrowers, and guarantors, whose land/apartment properties have been mortgaged/attached. Furthermore, this notice prohibits any private transfer, creation of encumbrance, or pledging of the said immovable properties after the date of this notice.

Sr. No.	Defendant's name	Date of Recovery Certificate, Date of Demand Notice, Seizure order dated, Symbolic Possession Date	Description of real estate
1.	Mr. Anand Mahadev Bhagat (Borrower) Address: B-101, Centurion Park, Premnagar, Chinchpada, Tal. Pen, Dist. Raigad. 1) Mr. Mitesh Khatav Bhanushali (Co-borrower) 2) Mr. Dinesh Haresh Shah (Co-borrower)	Recovery Certificate Date - 10/11/2023 Recoverable Amount - 17,03,314/- (As per the recovery certificate) Demand Notice Date - 19/12/2023 Attachment Order Date - 02/03/2024 Possession Notice Date - 07/10/2025	Land property located within the boundaries of village Mauje Dushmi, Pen Taluka, Raigad District. Survey No. 63/9, Area 0-07-80 hectares, registered in the name of the borrower, Mr. Anand Mahadev Bhagat

This public notice was issued on 05/02/2026 with my signature and official seal.

Ref. No. Bhairavnath N.Pat/Possession/662/2026  
Dated 05/02/2026

Mr. Shyam Dnyaneshwar Gawade  
Authorized Special Recovery Officer



Maral Overseas Limited



PROUD TO BE INDIAN  
PRIVILEGED TO BE GLOBAL

EXTRACT OF UNAUDITED FINANCIAL RESULTS  
FOR THE QUARTER AND NINE MONTHS ENDED 31<sup>ST</sup> DECEMBER, 2025

(₹ In Lakhs except per share data)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
Total Income from operations (Net)	25,171.46	25,435.53	25,495.80	73,620.37	78,812.01	1,06,960.29
Net Profit (+)/Loss (-) for the period (before tax, exceptional and / or extra ordinary items)	627.36	(313.77)	(1,139.28)	(961.81)	(2,520.11)	(2,563.15)
Net Profit (+)/Loss (-) for the period before tax (after exceptional and/or extra ordinary items)	567.53	(313.77)	(1,139.28)	(1,021.64)	(2,520.11)	(2,563.15)
Net Profit (+)/Loss (-) for the period after tax (after exceptional and/or extra ordinary items)	530.49	(278.46)	(1,056.44)	(1,004.95)	(2,397.11)	(2,419.71)
Total Comprehensive Income for the period (Comprising Profit (+)/Loss (-) for the period (after tax) and other comprehensive income (after tax)	619.20	(361.60)	(1,065.47)	(1,042.88)	(2,335.11)	(2,264.79)
Equity Share Capital	4,150.80	4,150.80	4,150.80	4,150.80	4,150.80	4,150.80
Other Equity (reserves) as shown in the Balance Sheet	-	-	-	-	-	6,738.26
Earning Per Share (Equity shares of face value of Rs.10/- each) (before and after Extra ordinary items) (EPS for the quarter/period not annualised)						
- Basic	1.28	(0.67)	(2.55)	(2.42)	(5.77)	(5.83)
- Diluted	1.28	(0.67)	(2.55)	(2.42)	(5.77)	(5.83)

Notes:

- The above is an extract of detailed format of unaudited financial results for the quarter and nine months ended 31<sup>st</sup> December, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed unaudited financial results and this extract were reviewed and recommended by Audit Committee and approved by Board of Directors in their respective meeting held on 5<sup>th</sup> February, 2026. The full format of the unaudited financial results are available on the Stock Exchanges websites ([www.bseindia.com](http://www.bseindia.com), [www.nseindia.com](http://www.nseindia.com)) and on the Company's website ([www.maraloverseas.com](http://www.maraloverseas.com)).
- The Statutory Auditor has reviewed the results for the quarter and nine months ended 31<sup>st</sup> December, 2025 and issued an unqualified limited review report.
- Effective 21<sup>st</sup> November 2025, the Government of India consolidated 29 existing labour regulations into 4 Labour Codes, referred to as the "New Labour Codes". The New Labour Codes have resulted in an increase in the provision for employee benefits on account of recognition of past service costs. Based on the requirements of the New Labour Codes and the relevant Accounting Standard, the Company has assessed and accounted for the estimated incremental impact of Rupees 59.83 Lakh as an Exceptional Item in the statement of profit and loss for the quarter and nine months ended 31<sup>st</sup> December 2025.Upon notification of the related Rules to the New Labour Codes by the Central/State Government and any further clarification on other aspects of the New Labour Codes, the Company will evaluate and account for additional impact, if any, in subsequent periods.
- The Company has no Subsidiary, Associate or Joint Venture company(ies), as on 31<sup>st</sup> December, 2025.



By order of the Board  
For Maral Overseas Limited  
Sd/-  
Shekhar Agarwal  
Chairman & Managing Director and CEO  
DIN: 00066113

Place : Noida (U.P.)  
Dated : 05<sup>th</sup> February, 2026

Registered Office: Maral Sarovar, V. & P.O. Khalbujurg, Tehsil Kasrawad, Distt. Khargone - 451 660, (M.P.)  
Phone: +91-7285-265401-265405; CIN : L17124MP1989PLC008255  
Corporate Office: Bhilwara Towers, A-12, Sector-1, Noida - 201 301, (U.P.), Phone: +91-120-4390300 (EPABX)  
E-mail: maral.investor@njbhillwara.com Website: [www.maraloverseas.com](http://www.maraloverseas.com)



State Bank of India, Stressed Assets Recovery Branch  
3rd Floor, Matrix Mall, Sector- 4, Jawahar Nagar, Jaipur  
(Rajasthan) -302004, E-mail : [sbi.18184@sbi.co.in](mailto:sbi.18184@sbi.co.in),  
Tel.: 0141-2657811, 2657921, 2657926, 2657989

Appendix – II-A and IV-A [See Provision to rule 6(2) and 8(6)]  
E-AUCTION SALE NOTICE FOR SALE OF MOVABLE  
& IMMOVABLE ASSETS UNDER SARFAESI ACT

E-Auction Sale Notice for Sale of Movable & Immovable Assets under the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002 read with proviso to Rule 8(6) of the Security Interest (Enforcement) Rules, 2002.

Notice is hereby given to the public in general and in particular to the Borrower(s)/ Guarantor(s) that the below described movable & immovable assets mortgaged/hypothecated to the Secured Creditor, the physical possession of which has been taken by the Authorised Officer of State Bank of India, Stressed Assets Recovery Branch (SARB), Jaipur (Raj.), the Secured Creditor, will be sold on "As is Where is", "As is What is", "Whatever there is" and "Without recourse" basis on 26.02.2026 (Date of Auction) for recovery of under mentioned amount plus further interest, cost, charges & other expenses etc. due to the secured creditor from below mentioned Borrower(s)/ Guarantor(s). Interested bidder may deposit Pre-Bid EMD) amount shall be paid online i.e. through NEFT after generation of Challan from (<https://baanknet.com>) in bidders Global EMD Wallet, before the close of e-Auction. Credit of Pre-bid EMD shall be given to the bidder only after receipt of payment in Bank account and updation of such information in the e-auction website. This may take some time as per banking process and hence bidders, in their own interest, are advised to submit the pre-bid EMD amount well in advance to avoid any last-minute problem.

E-Auction Date & Time:- 26.02.2026 from 11.00 AM to 03.00 PM; Auction Portal:- <https://baanknet.com>

Sr. No.	Name of the Borrowers/ Guarantors	Outstanding Amount	Description of the Immovable Properties	Reserve Price EMD Amount	Contact Person Name & Mob. No.
1.	Smt. Parul Amit Srivastava W/o Sh. Amit Srivastava and Mr. Amit Srivastava S/o Sh. G.S. Srivastava (Borrower)	Rs. 50,05,789.00 as on 20.12.2025 plus Further interest, cost, charges & other expenses etc:	Equitable Mortgage of Residential Property situated at Flat No. D-406, 4Th Floor, d Wing Building Known as IRVETTA, Project known as CASA RIO GOLD Situated at Village- Nilje, Tehsil-Kalyan, Dist. Thane (Maharashtra) admeasuring area 495 sq. ft. (Carpet) along with one (4-wheeler) open car parking space in the name of Mrs.-Parul Amit Srivastava and Mr. Amit Srivastava.	Rs. 51,50,000/- Rs. 5,15,000/-	ASHISH GUPTA 7357044666

Encumbrances: - Not known apart from as above.

For detailed terms and conditions of the sale, please refer to the link provided in State Bank of India, Stressed Assets Recovery Branch (SARB), Jaipur (Raj.) Secured Creditor's <https://sbi.co.in/web/sbi-in-the-news/auction-notices/sarfaesi-and-others> or <https://baanknet.com> (Auction Portal).

Date: 06.02.2026 Place: Thane

Authorised Officer, State Bank of India



Engineering Services

IL&FS ENGINEERING AND CONSTRUCTION COMPANY LIMITED

CIN: L45201TG1988PLC008624


Regd. Office: D.No.8-2-120/113, B-Block, 1st Floor, Sanali Info Park, Road No. 2, Banjara Hills, Hyderabad - 500033  
Ph: 040-40409333; Fax: 040-40409444; Email: [cs@iflsengg.com](mailto:cs@iflsengg.com); Web: [www.iflsengg.com](http://www.iflsengg.com)

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine months ended 31<sup>st</sup> December, 2025 ("Financial Results") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on Thursday, February 05, 2026.

The said Financial Results along with the Auditors Report have been posted on the Company's webpage at <https://www.iflsengg.com/News/comm2exchange/2025-26/Results-Dec25.pdf> and on the websites of the Stock Exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) and can be accessed by scanning the QR Code provided below:



For and on behalf of Board of Directors  
IL&FS Engineering and Construction Company Limited  
sd/-

KAZIM RAZA KHAN  
Chief Executive Officer

Place: Gurugram  
Date: 05.02.2026



UNICHEM  
LABORATORIES LTD.

CIN:L99999MH1962PLC012451

Registered Office:47, Kandivli Industrial Estate, Kandivli (West), Mumbai - 400067, Maharashtra, India  
Website: [www.unichemlabs.com](http://www.unichemlabs.com); E-mail Id.: [shares@unichemlabs.com](mailto:shares@unichemlabs.com); Tel.: (022) 66474100

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND  
NINE MONTHS ENDED 31ST DECEMBER, 2025

Sr. No.	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total income from operations	521.17	578.96	533.09	1,626.73	1,523.79	2,110.97
2	Net Profit / (Loss) for the period (before tax and exceptional items)	17.91	47.44	61.85	56.33	96.79	154.59
3	Net Profit / (Loss) for the period before tax (after exceptional items)	293.43	(10.82)	61.85	273.59	96.79	154.59
4	Net Profit / (Loss) for the period after tax (after exceptional items)	264.29	(11.89)	57.85	241.93	84.55	137.52
5	Total comprehensive income for the period [comprising of profit / (loss) for the period (after tax) and other comprehensive income (after tax)]	262.22	(10.04)	59.71	244.76	83.85	130.55
6	Paid-up Equity Share Capital	14.08	14.08	14.08	14.08	14.08	14.08
7	Other Equity [Reserves excluding Revaluation Reserve]						2,421.81
8	Earnings per equity share (Face value of ₹ 2/- per share) (not annualized)						
(a) Basic		37.54	(1.69)	8.22	34.36	12.01	19.53
(b) Diluted		37.47	(1.69)	8.19	34.29	11.97	19.47

Notes:

- The above unaudited consolidated financial results ("the Statement") for the quarter and nine months ended 31<sup>st</sup> December, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 5<sup>th</sup> February, 2026. The statutory auditors have expressed an unmodified audit conclusion on these consolidated financial results for the quarter and nine months ended 31<sup>st</sup> December, 2025. The above is an extract of the detailed format of the consolidated financial results for the quarter and nine months ended 31<sup>st</sup> December, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these Financial Results are available on the Stock Exchange websites ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)) and on the website of the Company ([www.unichemlabs.com](http://www.unichemlabs.com)).
- Effective from 30<sup>th</sup> April, 2025 Unichem Laboratories Ireland, has ceased to be subsidiary of the Company. For the purpose of consolidation, figures of the subsidiary have been considered upto the aforesaid date and net gain of ₹ 1.99 crores have been recognised in the nine months ended 31<sup>st</sup> December, 2025 under other income.
- The Company and its subsidiary Niche Generics Ltd. ("Niche") had received a demand order dated 17<sup>th</sup> September 2025 from the European Commission (EU) for payment of fine and interest aggregating to Euro 19.55 million and the same is fully settled by the Company on 28<sup>th</sup> October 2025 after adjusting the payments of Euro 2.79 million already made by Niche in instalments to EU. In regard to above, the Company had fully recognised a provision in books towards payment of fine amounting to Euro 13.96 million towards EU fine during year ended 31<sup>st</sup> March 2024 and the balance amount representing the interest is recorded in quarter ended 30<sup>th</sup> September 2025 and nine months ended 31<sup>st</sup> December 2025 under exceptional items.

4. Additional Information on Unaudited Standalone Financial Results for the Quarter and Nine Months ended 31<sup>st</sup> December, 2025 is as follows:

Sr. No.	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total income from operations	314.90	356.90	447.83	1,056.05	1,274.46	1,735.70
2	Profit / (Loss) before exceptional items and tax	(15.70)	(4.69)	61.80	(22.26)	126.65	178.68
3	Profit/(Loss) before tax	259.82	(37.83)	61.80	220.12	126.65	182.68
4	Profit/(Loss) after tax	216.11	(39.93)	46.89	174.33	111.74	162.96



Place: Mumbai  
Date: 5<sup>th</sup> February, 2026

By Order of the Board  
For Unichem Laboratories Limited  
Sd/-  
Pabitrakumar Kalipada Bhattacharyya  
Managing Director  
DIN : 07131152



## HEALTHCARE GLOBAL ENTERPRISES LIMITED

Regd Off: HCG Towers, # 8, P Kalinga Rao Road, Sampangi Ram Nagar, Bangalore – 560027

CIN: L15200KA1998PLC023489

Phone: +91 – 80 – 4660 7700, Fax: +91 – 80 – 4660 7749

Email: investors@hcgel.com; Website: www.hcgoncology.com



### EXTRACT OF THE CONSOLIDATED & STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

Particulars	Consolidated				Standalone			
	(Amount in Rs. Lakhs)				(Amount in Rs. Lakhs)			
	Quarter ended 31 December 2025	Corresponding quarter ended 31 December 2024	Nine months ended 31 December 2025	Previous year ended 31 March 2025	Quarter ended 31 December 2025	Corresponding quarter ended 31 December 2024	Nine months ended 31 December 2025	Previous year ended 31 March 2025
	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
Total income	63,554	56,321	190,500	225,766	34,515	31,780	102,984	131,510
Net profit/ (loss) for the period (before tax and exceptional items)	660	(330)	3,834	5,696	659	(156)	2,643	5,440
Exceptional items, net gain / (loss)	(1,267)	-	(1,267)	-	(786)	(3,482)	(786)	(3,482)
Net profit/ (loss) for the period (after tax and exceptional items)	(790)	775	1,874	4,883	(118)	(3,733)	1,305	353
Net profit / (loss) for the period attributable to equity share holders of the company	(943)	698	1,159	4,441	(118)	(3,733)	1,305	353
Total comprehensive income/(loss) for the period (Comprising net profit and other comprehensive income after tax) attributable to equity share holders of the company	(792)	758	1,405	4,602	(88)	(3,734)	1,324	383
Equity share capital	14,101	13,940	14,101	13,942	14,101	13,940	14,101	13,942
Earnings per share (of Rs.10 each) in Rs.Basic:	(0.68)	0.50	0.82	3.19	(0.08)	(2.68)	0.94	0.25
Earnings per share (of Rs.10 each) in Rs.Diluted:	(0.68)	0.49	0.82	3.14	(0.08)	(2.64)	0.93	0.25

#### Notes:

1. The above results were reviewed by the audit committee and approved by the board of directors at their meeting held on 05 February 2026.

2. The above is an extract from the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the NSE Limited ([www.nseindia.com](http://www.nseindia.com)), BSE Limited ([www.bseindia.com](http://www.bseindia.com)) and at the Company's website ([www.hcgoncology.com](http://www.hcgoncology.com)).



Bengaluru, 5 February 2026

For HealthCare Global Enterprises Limited  
Sd/-  
Dr. Manish Mattoo  
Executive Director and Chief Executive Officer